What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 3

Experienced a 'double miss' on earnings resulting in an 8% drop, though retail investor positioning remains long.

Trading at a significant discount with an EV/GP/RG of 0.11; the market has not priced in the Eucalyptus acquisition or the rollout of branded GLP-1 products.

Potential removal of FDA Commissioner Marty Makary is seen as a bullish catalyst that could ease regulatory pressure on the company's compounded GLP-1 medications.

Author views the recent 47% decline as a long-term buying opportunity despite volatility, noting a 5.09% daily gain to $29.71.

Positioned as a 'peptide trade' with a massive addressable market for weight loss and hair growth treatments.

High consumer demand for peptides and 34% short interest ahead of earnings; risk of Novo Nordisk lawsuit and margin compression from Wegovy distribution.

Vanguard established a massive 20.9 million share position; high short interest of 34% suggests potential for a short squeeze.

High-conviction trade based on weight loss/peptide demand and potential for a short squeeze due to 34% short interest.

High short interest of 35% creates short squeeze potential, while AI integration and a more favorable regulatory environment at the FDA serve as significant bullish catalysts.

High social media sentiment and 34% short interest suggest potential for a short squeeze ahead of Q1 earnings, with recent insider or large-scale buying at $26.72.

Mentioned as a relevant ticker in the current market discussion.

Expected to benefit from lighter enforcement on compounded GLP-1s and telehealth services under new FDA leadership.

Investor is all-in at $26.72, anticipating a short squeeze due to 34% short interest and earnings on May 11, despite a lawsuit from Novo Nordisk.

Trading at an extremely cheap valuation despite strong growth and new GLP-1 partnerships.

The restoration of mail-order access for Mifepristone supports the growth of telehealth platforms specializing in reproductive health.

Host took a position based on personal product usage and following moves by respected community analysts.

Host exited position warning of a potential cool-down after a successful trade leg.

Highlighted as a retail 'hallucination yield' play driven by AI suggestions.

Viewed as a less attractive alternative to LFMD which owns its own supply chain.

Positive price action described as a 'sick candle' indicating strong upward momentum.

Highly bullish following a partnership with Eli Lilly; market reaction is considered muted relative to the deal's scale.

Described as having 'lost its juice' after a pump-and-dump reaction to a partnership announcement.

Contrarian long view at the $19 price level.

Stock rose 6% following a partnership with Eli Lilly for weight-loss drug access.

Transitioning to a high-margin tech-like business model by distributing Eli Lilly's GLP-1 drugs; strong cross-selling potential and AI-driven high-margin membership fees.

Facing pressure following Amazon's entry into the GLP-1 weight loss market.

Primary trade for the peptide and GLP-1 legalization trend, though facing competitive pressure from Amazon.

Discussed as a headline trade regarding reclassifications of weight-loss drugs.

Facing a fundamental shift and moat erosion after Amazon's One Medical launched a competing, lower-priced GLP-1 program.

While HIMS is seen as the industry standard for telehealth distribution, it faces long-term disruption risks from high-traffic influencers who may pivot from promoters to competitors by launching their own private-label platforms.

Amazon's entry into the GLP-1 and oral medication space threatens the company's margins and moat.

Stock fell 9% as Amazon enters the GLP-1 market, threatening the company's competitive moat.

Recent exit after 75% gain; belief that the market has priced in the RFK Jr. peptide narrative and attention has peaked.

Significant upside potential driven by the peptide narrative, vertical integration, and AI-driven diagnostics despite high volatility.

Mentioned in the context of 'look-maxing' and hair-loss prevention products.

Maintained as a core high-conviction growth holding despite recent market volatility.

Viewed as a high-momentum 'attention trade' tied to potential FDA regulatory shifts and GLP-1 trends, though faces risks from high P/E and lack of a proprietary moat.

Viewed as a high-conviction momentum trade driven by potential regulatory shifts for peptides and a self-reinforcing product flywheel.

Aligned with the longevity revolution and AI-driven healthcare trends, focusing on peptides and health optimization.

Significant growth catalyst from entry into GLP-1 and peptide manufacturing following a facility acquisition, coupled with a potential TAM expansion for TRT and a resilient direct-to-consumer business model.

Up 11% on peptide rumors; high short interest of 40% makes it a candidate for a short squeeze.

Primary way for traders to play the high-growth peptide and biotech regulation narrative.

Momentum trade driven by internet narratives and political mentions.

High-conviction short squeeze candidate following loosening of peptide restrictions.

The speaker remains invested despite high volatility, viewing peptides as a potential catalyst for long-term tech disruption.

Positioned as a primary play for the 'looksmaxxing' trend, though historically volatile and momentum-driven.

Regulatory de-risking of peptides and high short interest create a major revenue catalyst and short squeeze potential.

Positioned to lead the legitimate peptide market through regulatory clarity, in-house manufacturing, and a move toward partnerships with big pharma.

Surged on news of FDA moving toward regulatory clarity for peptide therapy.

Utilizes 'MedMatch' AI for personalized prescriptions and is undervalued as an underlying AI-driven platform rather than just a GLP-1 play.